Defensive Disclosure for US12264345B1: PH20 Polypeptide Variants, Formulations and Uses Thereof

This defensive disclosure aims to broaden the prior art landscape related to PH20 polypeptide variants, their formulations, and uses, thereby rendering future incremental improvements by competitors obvious or non-novel. The derivations focus on core claims 1, 18, 19, 22, and 23 of US12264345B1.

---

Derivative Variations for Core Claim 1: Modified PH20 Polypeptide

Core Claim 1: A modified PH20 polypeptide that exhibits increased stability containing an amino acid replacement in a PH20 polypeptide that confers the increased stability, wherein increased stability is manifested as increased resistance to denaturation in the presence of one or more protein denaturation conditions, stability is increased compared to the PH20 polypeptide not containing the amino acid replacement, and the unmodified PH20 polypeptide consists of the sequence of amino acids set forth in SEQ ID NO: 7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide or has at least 85% sequence identity thereto.

1. Material & Component Substitution Derivatives

Derivative 1.1: Non-Natural Amino Acid Incorporation for Enhanced Stability

• Enabling Description: This derivative involves a modified PH20 polypeptide where specific amino acid replacements, particularly those identified in claim 15 or 16 (e.g., P204, R58), are substituted with non-natural amino acids designed for increased hydrophobicity, steric bulk, or the ability to form novel intermolecular cross-links. For example, replacing a native amino acid with p-acetylphenylalanine (pAcF) at a solvent-exposed site to introduce a keto group capable of forming covalent bonds with hydrazine-modified excipients, thereby anchoring the polypeptide within a formulation matrix. Alternatively, the incorporation of N-methyl-amino acids to reduce flexibility of specific loops, enhancing resistance to proteolytic degradation or thermal denaturation. The incorporation is achieved via amber codon suppression or chemically ligated peptide fragments.
• Mermaid Diagram:

  graph TD
      A[Unmodified PH20 Gene] --> B{Amber Codon Mutation at Target Site}
      B --> C[mRNA with Amber Codon]
      C --> D{Cell-free Protein Synthesis System}
      D --> E{tRNA Synthetase + non-natural AA}
      E --> F[Modified PH20 Polypeptide with non-natural AA]
      F --> G{Stability Assay}
      G --> H[Increased Stability]
  

Derivative 1.2: Polypeptide Backbone Modifications for Protease Resistance

• Enabling Description: This variation introduces D-amino acids or α-peptoid monomers into the polypeptide backbone at regions known to be susceptible to proteolytic cleavage, thereby increasing the overall stability of the PH20 polypeptide in biological systems or harsh processing environments. For instance, specific peptide bonds susceptible to endopeptidases (e.g., between residues 200-210 based on typical trypsin/chymotrypsin sites in similar enzymes) can be replaced with D-amino acid linkages or a peptoid unit via solid-phase peptide synthesis or segment ligation, which are not recognized by native proteases. This modification maintains the overall three-dimensional structure necessary for hyaluronidase activity while enhancing in vivo half-life.
• Mermaid Diagram:

  graph TD
      A[Unmodified PH20 Sequence] --> B{Identify Protease Cleavage Sites}
      B --> C{Design D-AA/Peptoid Substitutions}
      C --> D[Synthetic Gene Design]
      D --> E{Recombinant Expression / Chemical Ligation}
      E --> F[Protease-Resistant PH20]
      F --> G{Protease Stability Assay}
      G --> H[Increased Stability]
  

2. Operational Parameter Expansion Derivatives

Derivative 1.3: Cryostable PH20 for Long-Term Storage

• Enabling Description: This derivative focuses on engineering PH20 variants that maintain high hyaluronidase activity and structural integrity after prolonged storage at cryogenic temperatures (e.g., -80°C or in liquid nitrogen at -196°C) and subsequent thawing cycles. This involves amino acid replacements that enhance internal hydrogen bonding networks or increase the packing density of the protein core, which minimize cold denaturation and ice crystal formation damage. For example, substituting surface-exposed polar residues with non-polar ones to reduce ice-binding propensity, or introducing additional disulfide bonds (e.g., Cys replacements at positions 100 and 250 in SEQ ID NO:3, followed by oxidative folding) to rigidify the structure at low temperatures. Stability is assessed by measuring residual activity after multiple freeze-thaw cycles.
• Mermaid Diagram:

  stateDiagram-v2
      [*] --> Unmodified_PH20
      Unmodified_PH20 --> Engineering_for_Cryostability : Add disulfide bonds/Hydrophobic residues
      Engineering_for_Cryostability --> Cryostable_PH20_Variant
      Cryostable_PH20_Variant --> Freeze_Thaw_Cycle_1 : -196C
      Freeze_Thaw_Cycle_1 --> Thaw_Measure_Activity : Repeat 5-10x
      Thaw_Measure_Activity --> Increased_Cryostability : Compare to WT PH20
  

Derivative 1.4: PH20 Variant for High-Radiation Environments

• Enabling Description: This variant is engineered for stability under ionizing radiation (e.g., gamma irradiation, electron beam sterilization). This is achieved by introducing amino acid replacements that reduce the formation of reactive oxygen species (ROS) or enhance intrinsic radical scavenging capabilities. For example, replacing methionine (Met) and tryptophan (Trp) residues, which are highly susceptible to oxidation, with more stable analogs like norleucine or 5-fluorotryptophan, respectively, at non-catalytic sites. Additionally, introducing mutations that increase the overall protein surface charge or enhance protein-water interactions can provide a protective hydration shell against indirect radiation damage. The efficacy is evaluated by exposing the variant to controlled doses of gamma radiation (e.g., 25-50 kGy) and assessing retention of enzymatic activity and structural integrity via CD spectroscopy.
• Mermaid Diagram:

  graph TD
      A[Unmodified PH20] --> B{Identify Radiation-Sensitive Residues (Met, Trp)}
      B --> C{Replace with Radiation-Tolerant Analogs (Nle, 5F-Trp)}
      C --> D[Modified PH20 Variant]
      D --> E{Irradiation Treatment (e.g., Gamma 25 kGy)}
      E --> F{Activity & Structural Integrity Assay}
      F --> G[Increased Radiation Stability]
  

Derivative 1.5: PH20 for Extreme pH Stability

• Enabling Description: A PH20 polypeptide modified to exhibit increased stability and activity across extreme pH ranges (e.g., pH 2-4 or pH 9-11), significantly beyond the physiological neutral pH. This involves targeted amino acid substitutions that alter the pKa values of key residues involved in structural integrity and catalytic activity, or the introduction of additional salt bridges and hydrogen bonds that are stable under varying protonation states. For instance, substituting histidine residues with glutamic acid or aspartic acid at positions where a negative charge is desirable at low pH, or vice versa, substituting acidic residues with basic ones. This could also involve engineered surface glycosylation patterns to shield sensitive regions. The stability is confirmed by incubating the polypeptide in buffers of varying pH (e.g., 0.1 M Glycine-HCl pH 2.5, 0.1 M Tris-HCl pH 10.5) for extended periods and measuring residual hyaluronidase activity.
• Mermaid Diagram:

  graph LR
      A[Unmodified PH20] --> B{Identify pH-Sensitive Residues/Regions}
      B --> C{Introduce Charge-Stabilizing AA Replacements (e.g., His->Glu, Asp->Arg)}
      C --> D[pH-Stable PH20 Variant]
      D --> E{Incubation at pH 2.5}
      D --> F{Incubation at pH 10.5}
      E -- Retained Activity --> G[Increased Acid Stability]
      F -- Retained Activity --> H[Increased Alkaline Stability]
  

3. Cross-Domain Application Derivatives

Derivative 1.6: PH20 Variants for Industrial Bioreactor Applications

• Enabling Description: A modified PH20 polypeptide designed for use in industrial bioreactors, where it functions under conditions of high substrate concentration, elevated temperature (e.g., 45-60°C for increased reaction kinetics), and continuous shear forces due to mixing. The modifications include replacements that confer thermostability (as in claims 2, 3) and resistance to aggregation under high protein concentrations. This might involve introducing mutations that enhance oligomerization for stability or conversely, mutations that prevent non-specific aggregation in high-density media. The variant is immobilized on a robust, regenerable matrix (e.g., porous ceramic or magnetic nanoparticles) for continuous hyaluronan degradation in pharmaceutical intermediate production or biomaterial recycling.
• Mermaid Diagram:

  flowchart TD
      A[High Substrate HA Feed] --> B(Bioreactor Vessel)
      B --> C{Immobilized Thermostable PH20 Variant}
      C --> D[HA Degradation Products]
      C -- High Temp/Shear --> C
      D --> E(Product Separation)
      F[Modified PH20 Synthesis] --> C
  

Derivative 1.7: PH20 Variants for AgTech Soil Remediation

• Enabling Description: A PH20 polypeptide engineered for increased stability and activity in diverse soil environments, including those with varying pH, salinity, and microbial loads, to facilitate the breakdown of stubborn polysaccharide-based residues or to improve soil permeability for enhanced water and nutrient uptake. The variant incorporates amino acid replacements that provide resistance to soil-borne proteases and nucleases, UV radiation from sunlight, and heavy metal chelating effects. This could include surface modifications such as PEGylation (as mentioned in patent definitions) or glycosylation pattern alterations to protect the active site and extend residence time in soil. Application method involves granular formulation for direct soil amendment or incorporation into irrigation systems.
• Mermaid Diagram:

  sequenceDiagram
      User->>AgTech Company: Request Soil Permeability Improvement
      AgTech Company->>PH20 Engineering: Develop Soil-Stable PH20 Variant
      PH20 Engineering->>PH20 Engineering: Incorporate Protease/UV Resistance Mutations
      PH20 Engineering->>PH20 Engineering: Optimize Glycosylation/PEGylation
      PH20 Engineering->>AgTech Company: Deliver Granular PH20 Variant
      AgTech Company->>Soil: Apply Granular PH20
      Soil->>PH20 Variant: pH, Salinity, Microbes, UV Stress
      PH20 Variant->>Soil: Degrade Polysaccharides (HA-like)
      Soil->>User: Enhanced Permeability & Nutrient Uptake
  

Derivative 1.8: PH20 Variants for Biodegradable Plastic Additives

• Enabling Description: A modified PH20 polypeptide incorporated as an enzymatic additive into biodegradable plastics (e.g., polylactic acid (PLA) or polyhydroxyalkanoates (PHA)) containing hyaluronan or similar glycosaminoglycan-based plasticizers/fillers. The PH20 variant is engineered for long-term stability within the solid polymer matrix and controlled release/activation upon specific environmental triggers (e.g., moisture, specific pH, or UV exposure) to initiate or accelerate the degradation process of the plastic. This requires encapsulating the PH20 variant within a microcapsule that breaks down under trigger conditions, or engineering the PH20 itself to have a pro-enzyme state activated by environmental cues.
• Mermaid Diagram:

  classDiagram
      class Biodegradable_Plastic {
          +PolymerMatrix
          +HA_Plasticizer/Filler
          +Encapsulated_PH20_Variant
      }
      class PH20_Variant {
          +Enhanced_Stability_in_Polymer
          +Pro-Enzyme_State
          +Environmental_Trigger_Activation()
      }
      class Microcapsule {
          +Trigger_Sensitive_Shell
          +Contains_PH20_Variant
      }
      Biodegradable_Plastic "1" -- "1" PH20_Variant : Contains
      Biodegradable_Plastic "1" -- "1" Microcapsule : Incorporates
      Microcapsule ..> PH20_Variant : Releases
  

4. Integration with Emerging Tech Derivatives

Derivative 1.9: AI-Optimized PH20 for Multi-Denaturing Conditions

• Enabling Description: An AI-driven platform identifies and designs PH20 polypeptide variants with optimal stability across multiple denaturing conditions simultaneously (e.g., high temperature, low salt, and preservative presence, as in claims 2-9). A deep learning model, trained on large datasets of PH20 mutagenesis and stability data, predicts synergistic amino acid replacements that confer enhanced resistance to combinations of stresses. The AI generates novel polypeptide sequences, which are then synthesized, expressed, and experimentally validated. Real-time feedback from high-throughput screening informs further AI iteration and refinement of the design space.
• Mermaid Diagram:

  flowchart LR
      A[Experimental Stability Data] --> B(AI Training Data)
      B --> C{Deep Learning Model}
      C --> D[Predict Optimal AA Replacements]
      D --> E{Synthesize Novel PH20 Variant}
      E --> F[High-Throughput Stability Screening]
      F --> G{Multi-Denaturing Condition Testing}
      G -- Feedback Loop --> A
      G --> H[AI-Optimized Multi-Stable PH20]
  

Derivative 1.10: IoT-Monitored PH20 Formulation Stability

• Enabling Description: Modified PH20 formulations, potentially incorporating variants from Claim 1, are housed in smart pharmaceutical vials equipped with IoT sensors that continuously monitor critical stability parameters (temperature, pH, light exposure, aggregate formation via light scattering). This real-time data is transmitted to a cloud platform where AI algorithms predict shelf-life and potential degradation events. The system can trigger alerts for impending stability issues or dynamically suggest optimal storage conditions or usage protocols based on accumulated environmental exposure. This extends the principles of monitoring stability from claims 23-34.
• Mermaid Diagram:

  sequenceDiagram
      actor User
      Smart_Vial->>IoT_Sensors: Monitor Temp, pH, Light, Aggregation
      IoT_Sensors->>Cloud_Platform: Transmit Real-time Data
      Cloud_Platform->>AI_Algorithm: Analyze Stability Trends
      AI_Algorithm->>User: Alert for Degradation / Optimal Storage Suggestion
      User->>Smart_Vial: Act on Suggestions (e.g., move to cooler spot)
  

Derivative 1.11: Blockchain-Verified PH20 Supply Chain Integrity

• Enabling Description: The production, testing, and distribution of modified PH20 polypeptides are recorded on a permissioned blockchain network. Each batch of PH20 variant, along with its specific amino acid replacements, measured stability data (e.g., hyaluronidase activity under specific denaturation conditions as per claim 23), manufacturing date, and environmental conditions during transport, is immutably recorded as a series of linked blocks. This ensures transparent, tamper-proof verification of product authenticity, quality, and cold chain integrity from synthesis to patient, leveraging the increased stability of the PH20 variant to guarantee performance throughout the supply chain.
• Mermaid Diagram:

  graph TD
      A[PH20 Variant Synthesis] --> B(QC Testing & Stability Data)
      B --> C{Create Blockchain Transaction (Batch ID, AA Seq, Activity)}
      C --> D[Add Block to Network]
      D --> E[Logistics & Transport Monitoring (IoT Data)]
      E --> F{Create Blockchain Transaction (Temp, Humidity, GPS)}
      F --> D
      D --> G[Distribution & Pharmacy]
      G --> H{Verify PH20 Authenticity/Quality (Blockchain Query)}
      H --> I[Patient Administration]
  

5. The "Inverse" or Failure Mode Derivatives

Derivative 1.12: Environmentally-Triggered Degradable PH20

• Enabling Description: A PH20 polypeptide variant designed for controlled, rapid loss of activity and structural integrity under specific environmental cues, serving as a "biological fuse." Instead of increasing stability, amino acid replacements are engineered to introduce highly labile sites or conformational triggers. For example, replacing a hydrophobic core residue with a highly charged amino acid that induces unfolding at a specific ionic strength, or incorporating a light-sensitive amino acid (e.g., o-nitrobenzyl-cysteine) that cleaves the polypeptide upon UV exposure, leading to irreversible denaturation and inactivation. This variant could be used where transient hyaluronidase activity is desired, followed by rapid, localized clearance.
• Mermaid Diagram:

  stateDiagram-v2
      [*] --> Stable_Pro-PH20
      Stable_Pro-PH20 --> Exposure_to_Trigger : Light / pH Shift / Enzyme / Redox Change
      Exposure_to_Trigger --> Conformational_Change
      Conformational_Change --> Irreversible_Denaturation
      Irreversible_Denaturation --> Rapid_Activity_Loss
      Rapid_Activity_Loss --> Cleared_Products
      Cleared_Products --> [*]
  

Derivative 1.13: Low-Activity PH20 Variant for Tunable HA Modulation

• Enabling Description: A PH20 polypeptide engineered with specific amino acid replacements that reduce its hyaluronidase activity (e.g., 5-20% of wild-type activity) while maintaining stability. This could involve targeted mutations in or near the active site that slightly alter substrate binding affinity or catalytic efficiency without abolishing function. For example, a conservative amino acid substitution at a non-essential active site residue (e.g., D110N or E230Q in SEQ ID NO:3, if these were identified as activity-modulating) that still allows for HA cleavage but at a significantly slower rate. This "low-power" variant enables fine-tuned, prolonged, or localized hyaluronan degradation for applications requiring subtle modulation rather than rapid breakdown, such as in chronic tissue remodeling or sustained drug delivery matrices.
• Mermaid Diagram:

  graph LR
      A[Wild-Type PH20] --> B{Identify Activity-Modulating Residues (Active Site/Loops)}
      B --> C{Introduce Partial-Loss-of-Function AA Replacements (e.g., D110N)}
      C --> D[Low-Activity PH20 Variant]
      D --> E{HA Degradation Assay}
      E -- 5-20% WT Activity --> F[Tunable HA Modulation]
  

---

Derivative Variations for Core Claim 18: Composition with Excipient

Core Claim 18: A composition comprising the modified PH20 polypeptide of claim 1 and an excipient.

1. Material & Component Substitution Derivatives

Derivative 18.1: Modified PH20 with Ionic Liquid Excipients

• Enabling Description: A composition comprising the modified PH20 polypeptide (e.g., P204 variant from claim 17) formulated with a novel class of ionic liquid excipients, specifically biocompatible choline-based ionic liquids (e.g., choline chloride/urea deep eutectic solvent). These ionic liquids act as both solvent and stabilizing agents, replacing traditional aqueous buffers and phenolic preservatives (as in claim 6) which can be denaturing. The modified PH20 is engineered for compatibility and stability within this non-aqueous or mixed-aqueous environment, potentially requiring a higher degree of surface hydrophobicity or specific electrostatic interactions to prevent denaturation. Stability is assessed by retaining activity after storage in the ionic liquid for extended periods at ambient temperatures.
• Mermaid Diagram:

  graph TD
      A[Modified PH20 Polypeptide] --> B{Biocompatible Ionic Liquid Excipient}
      B -- Choline-based --> C[PH20-Ionic Liquid Composition]
      C --> D{Stability Assay (Ambient Temp)}
      D --> E[Increased Stability in Novel Excipient]
  

Derivative 18.2: PH20 Encapsulated in Biopolymeric Microspheres

• Enabling Description: The modified PH20 polypeptide is encapsulated within biodegradable polymeric microspheres (e.g., polylactide-co-glycolide (PLGA) or chitosan), where the polymer itself acts as the primary stabilizing excipient and provides controlled release. The PH20 variant is selected for its enhanced stability within the microencapsulation process (e.g., during solvent evaporation) and for sustained activity upon release. The encapsulation protects the enzyme from denaturing conditions like shear stress and specific chemical excipients, ensuring its integrity over prolonged periods. Release kinetics are tailored by polymer composition and size, allowing for pulsatile or continuous delivery.
• Mermaid Diagram:

  flowchart TD
      A[Modified PH20 Polypeptide] --> B(Encapsulation Process)
      B --> C{Biopolymeric Microspheres (PLGA/Chitosan)}
      C --> D[PH20-loaded Microsphere Composition]
      D --> E{Controlled Release (In vivo/In vitro)}
      E --> F[Sustained PH20 Activity]
  

2. Operational Parameter Expansion Derivatives

Derivative 18.3: Extreme Temperature-Resistant Excipient System

• Enabling Description: A composition comprising the modified PH20 polypeptide (e.g., variant optimized for 40°C stability from claim 3) and a cryoprotectant/thermoprotectant excipient system that allows for stable storage and activity across a wide temperature range, from sub-zero (e.g., -20°C) to elevated (e.g., 50°C). This system incorporates a combination of non-reducing sugars (e.g., trehalose, sucrose), high-molecular-weight polymers (e.g., PEG 8000), and specific amino acid derivatives (e.g., proline, arginine). The PH20 variant is designed to leverage these excipient interactions for optimal stability, and the formulation process ensures uniform dispersion and amorphous solid formation during lyophilization for long-term storage.
• Mermaid Diagram:

  graph LR
      A[Modified PH20 (Temp-stable)] --> B(Excipient Mix: Trehalose + PEG + Arginine)
      B --> C{Lyophilization Process}
      C --> D[Solid PH20 Formulation]
      D --> E{Storage at -20C}
      D --> F{Storage at 50C}
      E -- Retained Activity --> G[Broad Temp Stability]
      F -- Retained Activity --> G
  

3. Cross-Domain Application Derivatives

Derivative 18.4: PH20-Excipient for Textile Bio-Scouring

• Enabling Description: A composition for textile processing, specifically bio-scouring of natural fibers (e.g., cotton) to remove non-cellulosic impurities like pectins and waxes, where hyaluronan-like polysaccharides contribute to fiber stiffness. The modified PH20 polypeptide, formulated with a pH-buffering excipient system (e.g., sodium acetate/acetic acid) and a mild non-ionic surfactant, is engineered for stability and activity in the slightly alkaline (pH 8-9) and warm (50-60°C) conditions typical of textile wet processing. The PH20 component helps break down associated matrix components, improving water absorption and dye uptake without harsh chemicals.
• Mermaid Diagram:

  flowchart TD
      A[Raw Cotton Fiber] --> B(PH20-Excipient Composition)
      B -- pH 8-9, 55C --> C{Bio-Scouring Treatment}
      C --> D[Removal of Polysaccharide Impurities]
      D --> E[Softened, Absorbent Cotton]
  

---

Derivative Variations for Core Claim 19: Composition with Therapeutic Agent

Core Claim 19: A composition comprising the modified PH20 polypeptide of claim 1 and a therapeutic agent.

1. Material & Component Substitution Derivatives

Derivative 19.1: Modified PH20 with RNA Therapeutic Conjugates

• Enabling Description: A composition comprising the modified PH20 polypeptide and a chemically conjugated RNA therapeutic (e.g., siRNA, mRNA, antisense oligonucleotide). The PH20 variant is modified (e.g., through a C-terminal cysteine mutation and maleimide chemistry) to covalently link to the RNA therapeutic via a cleavable linker (e.g., disulfide bond, ester bond responsive to specific pH or enzyme). This conjugate targets hyaluronan-rich tissues (e.g., tumors) for localized HA degradation by PH20, thereby enhancing the penetration and bioavailability of the conjugated RNA therapeutic. The PH20 variant is engineered for stability against nucleases and proteases in vivo.
• Mermaid Diagram:

  graph LR
      A[Modified PH20 Polypeptide] --> B{Cleavable Linker Chemistry}
      B --> C[RNA Therapeutic]
      C --> D[PH20-RNA Conjugate]
      D --> E{HA-rich Tissue Target}
      E --> F[Localized HA Degradation]
      E --> G[Enhanced RNA Therapeutic Delivery]
  

Derivative 19.2: PH20 Co-formulated with Nanoparticle Drug Delivery Systems

• Enabling Description: A composition comprising the modified PH20 polypeptide co-formulated with drug-loaded nanoparticles (e.g., liposomes, polymeric nanoparticles encapsulating an anti-cancer drug like paclitaxel). The PH20 variant facilitates the penetration of these nanoparticles through the extracellular matrix, particularly in tissues with high hyaluronan content (e.g., solid tumors, as per patent definitions). The PH20 itself can be surface-bound to the nanoparticles or co-administered as a separate component in the same formulation. The PH20 variant is selected for increased stability in the presence of nanoparticle excipients (e.g., lipids, polymers) and maintaining activity in the biological environment.
• Mermaid Diagram:

  flowchart TD
      A[Drug-Loaded Nanoparticles] --> B(Modified PH20 Polypeptide)
      B -- Co-formulation --> C[Therapeutic Composition]
      C --> D{HA-Rich Biological Barrier}
      D -- PH20 Activity --> E[Reduced Barrier Viscosity]
      E --> F[Enhanced Nanoparticle Penetration]
      F --> G[Improved Drug Efficacy]
  

2. Operational Parameter Expansion Derivatives

Derivative 19.3: Thermosensitive PH20-Drug Conjugate for Hyperthermia Therapy

• Enabling Description: A composition comprising a modified PH20 polypeptide covalently linked to a chemotherapeutic agent (e.g., doxorubicin) via a thermosensitive linker. The PH20 variant itself is engineered to be highly stable at physiological temperatures but designed to undergo a localized conformational change or increased activity upon mild hyperthermia (e.g., 40-45°C), which is often used in cancer therapy. This dual mechanism ensures that the PH20-mediated HA degradation and subsequent drug release are precisely controlled by external temperature application, maximizing therapeutic effect at the heated site while minimizing systemic exposure. The thermosensitive linker could be a poly(N-isopropylacrylamide) (PNIPAM) derivative that collapses at the lower critical solution temperature (LCST) within the therapeutic hyperthermia range.
• Mermaid Diagram:

  stateDiagram-v2
      [*] --> PH20_Drug_Conjugate_Physiological_Temp
      PH20_Drug_Conjugate_Physiological_Temp --> HA_Degradation_Low : Low HA degradation
      PH20_Drug_Conjugate_Physiological_Temp --> Local_Hyperthermia_Applied : Target Site (40-45C)
      Local_Hyperthermia_Applied --> PH20_Activation_Thermosensitive_Linker_Cleavage : Increased PH20 activity and drug release
      PH20_Activation_Thermosensitive_Linker_Cleavage --> Enhanced_Drug_Delivery_Tumor : Localized HA degradation and drug delivery
      Enhanced_Drug_Delivery_Tumor --> Therapeutic_Effect : Increased anti-cancer activity
  

3. Cross-Domain Application Derivatives

Derivative 19.4: PH20-Therapeutic for Ocular Drug Delivery

• Enabling Description: A composition comprising a modified PH20 polypeptide and an ophthalmic therapeutic agent (e.g., anti-VEGF antibody for macular degeneration). The PH20 variant is specifically engineered for stability in the ocular environment (e.g., tear film pH, osmotic pressure, presence of lysozyme) and to enhance the penetration of the therapeutic agent across the vitreous humor and other ocular barriers. The PH20 modification ensures minimal immunogenicity while effectively reducing vitreous viscosity, allowing the larger therapeutic molecules to reach the retina more efficiently. The formulation is designed for intraocular injection, providing extended release.
• Mermaid Diagram:

  flowchart LR
      A[Modified Ocular-Stable PH20] --> B(Ophthalmic Therapeutic Agent)
      B -- Co-formulation --> C[Ocular Drug Composition]
      C --> D{Intraocular Injection}
      D --> E[Vitreous Humor Barrier]
      E -- PH20 Activity --> F[Reduced Vitreous Viscosity]
      F --> G[Enhanced Therapeutic Penetration to Retina]
  

---

Derivative Variations for Core Claim 22: Method for Increasing Stability of a PH20 Polypeptide

Core Claim 22: A method for increasing stability of a PH20 polypeptide, comprising introducing at least one amino acid replacement into the polypeptide, wherein the modified PH20 polypeptide exhibits increased stability compared to the PH20 polypeptide not containing the amino acid replacement, and the unmodified PH20 polypeptide consists of the sequence of amino acids set forth in SEQ ID NO: 7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide or has at least 85% sequence identity thereto.

1. Material & Component Substitution Derivatives

Derivative 22.1: Method Using Directed Evolution with Non-Canonical Amino Acids

• Enabling Description: A method to increase PH20 polypeptide stability by introducing amino acid replacements using a directed evolution approach that explicitly incorporates non-canonical amino acids (ncAAs). Instead of limiting replacements to the 20 natural amino acids, a genetic code expansion system (e.g., using orthogonal aminoacyl-tRNA synthetase/tRNA pairs) is employed to systematically introduce ncAAs with unique properties (e.g., enhanced hydrophobicity, aromaticity, or cross-linking capability) at specified positions. A library of PH20 variants with ncAA substitutions is generated and screened under denaturing conditions (e.g., high temperature, presence of specific excipients, as in claims 2-9) to identify variants with superior stability. This method extends the concept of amino acid replacement by expanding the chemical repertoire.
• Mermaid Diagram:

  flowchart TD
      A[PH20 Gene Library] --> B{Genetic Code Expansion System}
      B --> C[Incorporate Non-Canonical AAs (ncAAs)]
      C --> D[Library of ncAA-modified PH20]
      D --> E{High-Throughput Stability Screening (Denaturing Conditions)}
      E --> F[Select PH20 Variants with Increased Stability]
      F --> G[Characterize Optimal ncAA Replacements]
  

2. Operational Parameter Expansion Derivatives

Derivative 22.2: Method for Stability under Microgravity and Vacuum Conditions

• Enabling Description: A method for increasing PH20 polypeptide stability for applications in space environments, specifically microgravity and vacuum conditions. This involves amino acid replacements that enhance resistance to dehydration-induced denaturation and sublimation under vacuum. Lyophilized PH20 variants with specific mutations promoting intermolecular interactions (e.g., increased surface charge for self-assembly into protective structures, or engineered surface-exposed glycans that form a protective hydration layer) are prepared. Stability is assessed by exposing lyophilized samples to vacuum chambers mimicking space conditions (e.g., 10^-6 Torr) and then rehydrating and measuring hyaluronidase activity.
• Mermaid Diagram:

  graph TD
      A[Unmodified PH20] --> B{Targeted AA Replacements (Dehydration/Vacuum Resistance)}
      B --> C[Lyophilize PH20 Variant]
      C --> D{Simulated Microgravity/Vacuum Exposure}
      D --> E[Rehydration & Activity Assay]
      E --> F[Increased Stability in Space Conditions]
  

3. Cross-Domain Application Derivatives

Derivative 22.3: Method for PH20 Stability in Downhole Oil & Gas Applications

• Enabling Description: A method for increasing PH20 polypeptide stability for use in extreme downhole conditions (e.g., high pressure up to 20,000 psi, high temperature up to 150°C, and presence of corrosive brines and hydrocarbons) within the oil and gas industry. The modified PH20 would be used to degrade polysaccharide-based drilling fluids or filter cakes to improve permeability in reservoirs. Amino acid replacements are introduced to confer hyperthermostability (e.g., increasing disulfide bonds, reducing flexible loops, optimizing packing density), piezostability (resistance to high pressure-induced denaturation), and chemical resistance to common oilfield chemicals. This requires engineering a PH20 variant from a thermophilic extremophile PH20 homolog, further optimized with human PH20 (SEQ ID NO:7) features for desired specificity, if necessary.
• Mermaid Diagram:

  stateDiagram-v2
      [*] --> Unmodified_PH20
      Unmodified_PH20 --> Mutagenesis_for_Downhole : Hyperthermostability, Piezostability, Chemical Resistance
      Mutagenesis_for_Downhole --> Downhole_PH20_Variant
      Downhole_PH20_Variant --> High_Temp_High_Pressure_Test : 150C, 20k psi, Brine
      High_Temp_High_Pressure_Test --> Retained_Activity : Evaluate HA degradation
      Retained_Activity --> Increased_Downhole_Stability
  

---

Derivative Variations for Core Claim 23: Method for Identifying or Selecting a Modified Hyaluronan-Degrading Enzyme

Core Claim 23: A method for identifying or selecting a modified hyaluronan-degrading enzyme that exhibits stability under a denaturation condition, comprising the steps of: a) testing the activity of a modified hyaluronan-degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition; b) testing the activity of the corresponding unmodified hyaluronan-degrading enzyme in a composition containing the same denaturing agent and/or under the same denaturing condition as a), whereby the activity is tested under the same conditions as a); and c) selecting or identifying a modified hyaluronan-degrading enzyme that exhibits greater activity than the unmodified hyaluronan-degrading enzyme, thereby identifying or selecting a modified hyaluronan-degrading enzyme that exhibits increased stability under a denaturation condition.

1. Material & Component Substitution Derivatives

Derivative 23.1: Selection Method Using Quantum Dot-Based Activity Monitoring

• Enabling Description: A method for identifying stable hyaluronan-degrading enzymes using quantum dot (QD) FRET-based biosensors for real-time activity monitoring. Instead of traditional spectrophotometric assays, hyaluronan substrate is labeled with a FRET donor QD and an acceptor fluorophore. Cleavage of HA by the enzyme separates the donor and acceptor, resulting in a measurable change in fluorescence. This high-throughput system allows for continuous, sensitive monitoring of enzyme activity (step a and b of claim 23) in microfluidic droplets, even under highly turbid or colored denaturing conditions (e.g., presence of phenolic preservatives, as in claim 31, or complex excipient mixtures) that would interfere with conventional assays. The method permits selection of variants with enhanced activity over time (claim 11) using automated robotics.
• Mermaid Diagram:

  sequenceDiagram
      participant Modified_HDE_Library as Library
      participant HA_QD_Biosensor as Biosensor
      participant Microfluidic_System as Microfluidic
      participant Fluorescence_Detector as Detector
      participant Automated_Selection as Selector
  
      Library->>Microfluidic: Introduce HDE variants
      Microfluidic->>Biosensor: Add HA-QD substrate
      Microfluidic->>Microfluidic: Introduce Denaturing Condition
      Microfluidic->>Detector: Monitor QD FRET Signal (Real-time activity)
      Detector->>Selector: Transmit Activity Profiles
      Selector->>Selector: Compare Modified vs. Unmodified HDE (Claim 23c)
      Selector->>Library: Identify Stable HDE Variants
  

2. Operational Parameter Expansion Derivatives

Derivative 23.2: Selection Method under Extreme Pressure for Deep-Sea Enzymes

• Enabling Description: A method for identifying hyaluronan-degrading enzymes that are stable and active under extreme hydrostatic pressure, typical of deep-sea environments (e.g., 100-1000 atm). A high-pressure bioreactor system (e.g., a diamond anvil cell or a pressure-resistant microfluidic device) is used to perform activity assays (steps a and b of claim 23). Libraries of hyaluronan-degrading enzymes from piezophilic microorganisms or rationally designed variants (e.g., with specific amino acid replacements to increase packing density and reduce compressible voids in the protein structure) are tested. Selection (step c) is based on retaining hyaluronidase activity under elevated pressure compared to a control.
• Mermaid Diagram:

  graph TD
      A[HDE Library (Piezophilic/Engineered)] --> B(High-Pressure Bioreactor)
      B --> C{Introduce Denaturing Pressure (100-1000 atm)}
      C --> D{Perform Activity Assay (Modified HDE)}
      C --> E{Perform Activity Assay (Unmodified HDE)}
      D -- Activity @ Pressure --> F[Compare Activities]
      E -- Activity @ Pressure --> F
      F --> G[Select Piezostable HDE]
  

3. Cross-Domain Application Derivatives

Derivative 23.3: PH20 Selection Method for Biopharmaceutical Waste Treatment

• Enabling Description: A method to identify PH20 variants specifically adapted for degrading hyaluronan contaminants in complex biopharmaceutical waste streams. The denaturing conditions (claim 23a) include a diverse mixture of organic solvents, detergents (e.g., Triton X-114 mentioned in patent definitions), high salt concentrations, and varying pH, simulating industrial waste. The screening process integrates rapid analytical techniques like capillary electrophoresis or mass spectrometry to quantify hyaluronan degradation products from complex matrices. The PH20 variant selection (claim 23c) prioritizes enzymes that maintain significant activity and structural integrity under these multi-factorial inhibitory conditions, enabling efficient biological treatment of waste.
• Mermaid Diagram:

  flowchart TD
      A[HDE Library] --> B{Biopharmaceutical Waste Simulant (Denaturing Conditions)}
      B --> C(Activity Assay via Capillary Electrophoresis)
      C --> D{Compare Activity of Modified vs. Unmodified HDE}
      D --> E[Select Waste-Tolerant HDE Variant]
      E --> F[Application: Biopharma Waste Treatment]
  

---

Combination Prior Art Scenarios

Here are three combination prior art scenarios where US12264345B1 could be combined with existing open-source standards to demonstrate obviousness or non-novelty of future incremental improvements:

Combination Prior Art 1: PH20 Stability Screening with Open-Source Automated Liquid Handling

• Scenario: The methods described in claim 23 for identifying stable PH20 variants could be rendered obvious by combining them with established open-source automated liquid handling systems.
• Enabling Description: The high-throughput screening of modified hyaluronan-degrading enzymes (claim 23a, 23b, 35, 36) can be routinely implemented on an open-source robotic liquid handling platform, such as those programmable with the OpenTrons Python API (OT2). This platform, combined with publicly available protocols for enzyme assays (e.g., turbidity reduction assay for hyaluronidase activity) and standard denaturation conditions (e.g., elevated temperature controlled by the robot's thermocycler, or addition of common excipients like m-cresol at specified concentrations via automated pipetting), allows for the creation of extensive screening libraries and automated comparison (claim 23c). The OpenTrons API enables precise control over reagent addition, incubation times (claim 34), and plate reading, making the identification of stable variants a straightforward engineering task.

Combination Prior Art 2: PH20 Variant Design using Open-Source Protein Engineering Software

• Scenario: The design of modified PH20 polypeptides with amino acid replacements (claim 1, 15, 16) could be seen as obvious when leveraging open-source protein engineering tools and structural bioinformatics.
• Enabling Description: The process of introducing amino acid replacements for increased stability (claim 22) is directly informed by computational protein design using open-source software packages like Rosetta or MODELLER. These tools can predict the structural impact of specific amino acid substitutions on protein stability (e.g., free energy calculations, disulfide bond engineering, surface charge optimization) based on the known 3D structure of PH20 or homology models derived from SEQ ID NO:3 or SEQ ID NO:7. A skilled artisan, using these readily available and well-documented open-source platforms, can computationally identify candidate stabilizing mutations (e.g., at positions 204 or 58 as in claim 17) and then experimentally validate them, making the "introduction of an amino acid replacement" a predictable and iterative design process.

Combination Prior Art 3: PH20 Production in Open-Source E. coli Expression Systems

• Scenario: The production of modified PH20 polypeptides (implied by claims 1, 18, 19, 22, 23) using standard recombinant expression methods is routine and could be combined with open-source microbial expression systems.
• Enabling Description: The recombinant production of modified PH20 polypeptides (e.g., a soluble C-terminal truncated form as described in claim 1, such as SEQ ID NO:3) can be achieved using various open-source E. coli expression vectors and host strains. For instance, the BioBrick standard and associated plasmids (e.g., pSB1C3 or pET vectors adapted for BioBrick compatibility), widely documented and shared within the synthetic biology community, provide modular components for gene cloning, inducible expression (e.g., T7 promoter system), and protein purification (e.g., His-tag fusion). A DNA construct encoding a modified PH20 (derived from SEQ ID NO:7, for example) can be inserted into such a vector and expressed in an E. coli host (e.g., BL21(DE3) strain), followed by standard refolding and purification protocols to yield the active modified PH20 polypeptide, which can then be used in compositions (claims 18, 19) or stability assays (claims 23).